Lifeward Ltd., a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that it received prior authorization from Humana Medicare Advantage Plan for a ReWalk 7 Personal Exoskeleton. This marks the second national Medicare Advantage Plan, following UnitedHealthcare a few weeks ago, to make the important decision to support members living with spinal cord injury by facilitating access to this life-changing technology..

Lifeward Ltd. 是一家全球领先的创新医疗技术公司，致力于改变身体受限或残疾人士的生活，该公司今天宣布已获得 Humana Medicare Advantage 计划的预先授权，用于 ReWalk 7 个人外骨骼系统。这是继几周前 UnitedHealthcare 之后，第二个全国性的 Medicare Advantage 计划做出此项重要决定，通过促进脊髓损伤患者获取这项改变生活的技术来为其成员提供支持。

By approving coverage for the ReWalk 7 under its Medicare Advantage Plan, Humana continues to show leadership in embracing innovative medical technologies and widening reimbursement pathways for beneficiaries. The approval reflects Humana’s dedication to meeting the needs of members with disabilities and their families, providing more reliable and predictable access to personal exoskeletons as part of a comprehensive care strategy..

通过在其 Medicare Advantage 计划下批准 ReWalk 7 的覆盖范围，Humana 再次展现出其在接纳创新医疗技术及拓宽受益人报销途径方面的领导地位。这一批准反映了 Humana 致力于满足残疾成员及其家庭的需求，作为综合护理策略的一部分，为个人外骨骼提供更可靠和可预测的使用机会。

“Nationally nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for ReWalk 7,” said Mark Grant, CEO of Lifeward. “This prior authorization approval from a Humana Medicare Advantage Plan represents another significant milestone in payer adoption of the ReWalk Exoskeleton.

“在全国范围内，将近一半的 Medicare Advantage 参保人现在有资格获得 ReWalk 7 的事先授权和报销，”Lifeward 首席执行官 Mark Grant 表示。“这次从 Humana Medicare Advantage 计划获得的事先授权批准，代表了支付方对 ReWalk 外骨骼采用的另一个重要里程碑。”

As coverage broadens and prior authorizations accelerate, we are seeing stronger predictability in reimbursement, healthier cash flow dynamics, and a clearer foundation for scalable, sustainable growth in the U.S. market.”.

随着覆盖范围的扩大和事先授权的加快，我们在美国市场看到了更强的报销可预测性、更健康的现金流动态以及实现可扩展、可持续增长的更清晰基础。

In 2024, the Centers for Medicare & Medicaid Services (CMS) implemented a formal reimbursement pathway for personal exoskeletons. Since then, Lifeward has continued to submit claims on behalf of beneficiaries enrolled in both traditional Medicare and Medicare Advantage Plans. As payer adoption expands, the Company is experiencing an accelerating pace of prior authorization approvals, an encouraging signal of growing recognition of the clinical and functional value of personal exoskeleton technology..

2024年，美国医疗保险和医疗补助服务中心（CMS）为个人外骨骼设备实施了正式的报销途径。自此，Lifeward持续代表参与传统联邦医保和联邦医保优势计划的受益人提交理赔申请。随着支付方的采纳范围不断扩大，公司正经历越来越多的事先授权批准，这标志着个人外骨骼技术的临床和功能价值正逐渐得到认可，令人备受鼓舞。

About Lifeward

关于Lifeward

Lifeward designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings, as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities.

Lifeward 设计、开发并推广改变生活的解决方案，涵盖物理康复和恢复的整个护理过程，在临床环境、家庭及社区中提供经过验证的功能性和健康益处。Lifeward 的使命是不懈推动创新，以改变身体受限或残疾人士的生活。

We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products, including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany..

我们致力于提供开创性的解决方案，使个人能够做他们热爱的事情。Lifeward 产品组合包括创新产品，如 ReWalk 外骨骼、AlterG 反重力系统、ReStore 外套和 MyoCycle 功能性电刺激系统。Lifeward 成立于 2001 年，在美国、以色列和德国设有业务。

Lifeward®, ReWalk®, ReStore®, and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Lifeward®、ReWalk®、ReStore® 和 Alter G® 是 Lifeward Ltd. 及其关联公司的注册商标。

Forward-Looking Statements

前瞻性声明

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward looking statements may include projections regarding the Company's future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like 'anticipate,' 'assume,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'future,' 'will,' 'should,' 'would,' 'seek' and similar terms or phrases.

本新闻稿除包含历史信息外，还包含根据1995年美国《私人证券诉讼改革法案》、1933年美国《证券法》第27A条以及1934年美国《证券交易法》第21E条所定义的前瞻性陈述。这些前瞻性陈述可能包括对公司未来业绩的预测以及其他非历史事实的陈述，在某些情况下，可以通过诸如“预期”、“假设”、“相信”、“继续”、“可能”、“估计”、“期望”、“意图”、“或许”、“计划”、“潜在”、“预测”、“展望”、“未来”、“将”、“应该”、“会”、“寻求”以及类似词语或短语来识别。

The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward looking statements include, among others: the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients; the impact of reimbursements on Lifeward’s revenue and cash flow; uncertainties associated with future clinical trials and the clinical development process, the product development process and FDA regulatory submission review and approval process; the Company's ability to have sufficient funds to meet certain future capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; the Company's ability to maintain and grow its reputation and the market acceptance of its products; the Company's ability to ach.

本新闻稿中包含的前瞻性陈述基于管理层的当前预期，这些预期受到不确定性、风险以及难以预测且许多超出公司控制范围的情况变化的影响。可能导致公司实际结果与前瞻性陈述中所示结果存在重大差异的重要因素包括但不限于：医疗专业人士和患者对ReWalk 7个人外骨骼的接受程度；报销对Lifeward收入和现金流的影响；与未来临床试验及临床开发过程、产品开发过程和FDA监管提交审查及批准过程相关的不确定性；公司是否有足够的资金满足某些未来的资本需求，这可能会削弱公司在现有和新产品开发及商业化方面的努力；公司维护和提升其声誉以及市场对其产品接受度的能力；公司实现目标的能力。

Lifeward Media Relations:

生命守护媒体关系：

Almog Adar

阿尔莫格·阿达尔

Chief Financial Officer

首席财务官

E:

E:

[email protected]

电子邮件地址

Lifeward Investor Contact:

生命守护投资者联系人：

Almog Adar

阿尔莫格·阿达ർ

Chief Financial Officer

首席财务官

Lifeward

生命守护

E:

E:

[email protected]

电子邮件地址

Source: globenewswire.com

来源：globenewswire.com